



ACGME International

**Advanced Specialty Program Requirements for
Graduate Medical Education in
Renal Medicine (Nephrology)
(Internal Medicine)**

Reformatted: 1 April 2022
Revised: 12 December 2015, Effective: 1 July 2016
Initial Approval: 2 October 2012

ACGME International Specialty Program Requirements for Graduate Medical Education in Renal Medicine (Nephrology) (Internal Medicine)

Int. Introduction

Background and Intent: Programs must achieve and maintain Foundational Accreditation according to the ACGME-I Foundational Requirements prior to receiving Advanced Specialty Accreditation. The Advanced Specialty Requirements noted below complement the ACGME-I Foundational Requirements. For each section, the Advanced Specialty Requirements should be considered together with the Foundational Requirements.

Int. I. Definition and Scope of the Specialty

~~The medicine-based specialty of Renal medicine (nephrology) is the subspecialty of internal medicine that focuses on concern the diagnosis and treatment of diseases of the kidney diseases, including electrolyte disturbances and hypertension, and the care of those requiring renal replacement therapy, including dialysis and renal transplant patients.~~

Int. II. Duration of Education

Int. II.A. The educational program in renal medicine (nephrology) must be 24 or 36 months in length.

I. Institution

I.A. Sponsoring Institution

I.A.1. A fellowship in renal medicine (nephrology) must function as an integral part of an ACGME-I-accredited residency in internal medicine.

I.B. Participating Sites

See International Foundational Requirements, Section I.B.

II. Program Personnel and Resources

II.A. Program Director

See International Foundational Requirements, Section II.A.

II.B. Faculty

See International Foundational Requirements, Section II.B.

II.C. Other Program Personnel

II.C.1. There must be a close working relationship with dietary and/or nutrition services and social services, as well as with specialists in diagnostic radiology, general surgery, interventional nephrology and/or

50 interventional radiology, obstetrics and gynecology, pathology,
51 psychiatry, ~~vascular surgery~~, and urology.

52
53 **II.D. Resources**

54
55 II.D.1. The following laboratory and imaging services must be available at the
56 primary clinical site or at participating sites, including:

57
58 II.D.1.a) biochemistry and serologic laboratories; and,

59
60 II.D.1.b) ultrasound, computed tomography(CT), magnetic resonance
61 imaging-(MRI), and a diagnostic radionuclide laboratory.

62
63 II.D.2. There must be surgical and pathological support available for the modern
64 practice of renal medicine (nephrology), including an active renal
65 transplant service.

66 II.D.2.a) The primary clinical site must be approved to perform renal
67 transplantation or must have a formal written agreement with
68 such an institution, ensuring that renal medicine (nephrology)
69 fellows receive the requisite experience with renal
70 transplantation.

71
72 II.D.3. Surgery for vascular and peritoneal dialysis access must be available.

73
74 II.D.4. Electron and immunofluorescence microscopy and other special studies
75 for the preparation and evaluation of renal biopsy material must be
76 available.

77
78 II.D.5. The program must provide acute and chronic hemodialysis, continuous
79 renal replacement therapy, peritoneal dialysis, and renal biopsy service.

80 II.D.5.a) The program should be of sufficient size to ensure fellows'
81 adequate exposure to patients with acute kidney injury and end-
82 stage renal disease, including patients on chronic hemodialysis
83 and peritoneal dialysis, to ensure adequate education and
84 experience in chronic dialysis.

85 **III. Fellow Appointment**

86
87 **III.A. Eligibility Criteria**

88
89 III.A.1. Prior to appointment in the program, fellows should have completed an
90 ACGME-I-accredited residency program in internal medicine, or an
91 internal medicine residency program acceptable to the Sponsoring
92 Institution's Graduate Medical Education Committee.

93
94 **III.B. Number of Fellows**

95
96 See International Foundational Requirements, Section III.B.

97
98 **IV. Specialty-Specific Educational Program**

| | | |
|-----|-------------------|--------------------------------------------------------------------|
| 100 | IV.A. | ACGME-I Competencies |
| 101 | IV.A.1. | The program must integrate the following ACGME-I Competencies into |
| 102 | | the curriculum. |
| 103 | | |
| 104 | IV.A.1.a) | Professionalism |
| 105 | | |
| 106 | IV.A.1.a).(1) | Fellows must demonstrate a commitment to |
| 107 | | professionalism and an adherence to ethical principles. |
| 108 | | |
| 109 | IV.A.1.b) | Patient Care and Procedural Skills |
| 110 | | |
| 111 | IV.A.1.b).(1) | Fellows must provide patient care that is compassionate, |
| 112 | | appropriate, and effective for the treatment of health |
| 113 | | problems and the promotion of health. Fellows must |
| 114 | | demonstrate competence in managing the care of |
| 115 | | patients: |
| 116 | | |
| 117 | IV.A.1.b).(1).(a) | <u>in a variety of health care settings, including</u> |
| 118 | | <u>inpatient and ambulatory settings; the practice of</u> |
| 119 | | <u>health promotion, disease prevention, diagnosis,</u> |
| 120 | | <u>care, and treatment of men and women from</u> |
| 121 | | <u>adolescence to old age, during health and all</u> |
| 122 | | <u>stages of illness;</u> |
| 123 | IV.A.1.b).(1).(b) | <u>using critical thinking and evidence-based tools;</u> |
| 124 | IV.A.1.b).(1).(c) | <u>using population-based data; and,</u> |
| 125 | IV.A.1.b).(1).(d) | <u>with whom they have limited or no physical contact,</u> |
| 126 | | <u>through the use of telemedicine.</u> |
| 127 | | |
| 128 | IV.A.1.b).(2) | Fellows must demonstrate competence in the evaluation and |
| 129 | | management of: |
| 130 | IV.A.1.b).(2).(a) | acute kidney injury; |
| 131 | IV.A.1.b).(2).(b) | chronic kidney disease; |
| 132 | | |
| 133 | IV.A.1.b).(2).(c) | disorders of fluid, electrolyte, and acid-base |
| 134 | | regulation; |
| 135 | | |
| 136 | IV.A.1.b).(2).(d) | disorders of mineral metabolism, including |
| 137 | | nephrolithiasis and renal osteodystrophy; |
| 138 | | |
| 139 | IV.A.1.b).(2).(e) | drug dosing adjustments and nephrotoxicity |
| 140 | | associated with alterations in drug metabolism and |
| 141 | | pharmacokinetics in renal disease; |
| 142 | | |
| 143 | IV.A.1.b).(2).(f) | end-stage renal disease (<u>ESRD</u>), <u>including symptom</u> |
| 144 | | <u>management</u> ; |
| 145 | | |
| 146 | IV.A.1.b).(2).(g) | genetic and inherited renal disorders, including |

| | | |
|-----|-----------------------------------|----------------------------------------------------------------------|
| 147 | | inherited diseases of transport, cystic diseases, |
| 148 | | and other congenital disorders; |
| 149 | | |
| 150 | IV.A.1.b).(2).(h) | geriatric aspects of renal medicine (nephrology); |
| 151 | | |
| 152 | IV.A.1.b).(2).(i) | glomerular and vascular diseases, including the |
| 153 | | atheroembolic renal disease, diabetic nephropathy, |
| 154 | | and glomerulonephritides, ; |
| 155 | IV.A.1.b).(2).(j) | hypertensive disorders; |
| 156 | | |
| 157 | IV.A.1.b).(2).(k) | renal disorders of pregnancy; |
| 158 | | |
| 159 | IV.A.1.b).(3).(l) | renal transplant patients; |
| 160 | | |
| 161 | IV.A.1.b).(2).(l) | tubulointerstitial renal diseases; and, |
| 162 | | |
| 163 | IV.A.1.b).(2).(m) | urinary tract infections. |
| 164 | IV.A.1.b).(3) | <u>Fellows must be able to perform all medical, diagnostic, and</u> |
| 165 | | <u>surgical procedures considered essential to the subspecialty,</u> |
| 166 | | <u>including:</u> |
| 167 | IV.A.1.b).(3).(a) | <u>performing diagnostic and therapeutic procedures</u> |
| 168 | | <u>relevant to their individual specific planned career path,</u> |
| 169 | | <u>to include:</u> |
| 170 | | |
| 171 | IV.A.1.b).(4).(a).(i) | dialysis therapy; |
| 172 | | |
| 173 | IV.A.1.b).(1).(a).(ii) | performance of: |
| 174 | | |
| 175 | IV.A.1.b).(3).(a).(i) | acute and chronic hemodialysis; |
| 176 | | |
| 177 | IV.A.1.b).(3).(a).(ii) | continuous renal replacement therapy; |
| 178 | | |
| 179 | IV.A.1.b).(3).(a).(iii) | peritoneal dialysis; and, |
| 180 | | |
| 181 | IV.A.1.b).(3).(a).(iv) | placement of temporary vascular access for |
| 182 | | hemodialysis and related procedures. |
| 183 | IV.A.1.b).(3).(b) | <u>treating their patients' conditions with practices that are</u> |
| 184 | | <u>patient-centered, safe, scientifically based, effective,</u> |
| 185 | | <u>timely, and cost-effective, to include:</u> |
| 186 | IV.A.1.b).(3).(b).(i) | <u>delivering effective and patient-centered</u> |
| 187 | | <u>education regarding options for management</u> |
| 188 | | <u>of ESRD, including transplant, home dialysis</u> |
| 189 | | <u>therapies, in-center hemodialysis, and support</u> |
| 190 | | <u>care;</u> |
| 191 | IV.A.1.b).(3).(b).(ii) | <u>selecting patients for native or transplant</u> |
| 192 | | <u>kidney biopsy, including:</u> |

| | | |
|-----|----------------------------|----------------------------------------------------------------|
| 193 | IV.A.1.b).(3).(b).(ii).(a) | <u>interpretation and clinical</u> |
| 194 | | <u>application of results, and</u> |
| 195 | | <u>recognizing and managing</u> |
| 196 | | <u>adverse events; and,</u> |
| 197 | IV.A.1.b).(3).(b).(ii).(b) | <u>providing counsel to patients about</u> |
| 198 | | <u>the procedure, recognizing potential</u> |
| 199 | | <u>complications, and taking measures to</u> |
| 200 | | <u>reduce the risk of the procedure.</u> |
| 201 | IV.A.1.b).(3).(b).(iii) | <u>selecting patients for temporary dialysis</u> |
| 202 | | <u>access, identifying potential complications and</u> |
| 203 | | <u>taking measures to reduce the risk of the</u> |
| 204 | | <u>procedure, providing counsel to patients about</u> |
| 205 | | <u>the procedure, and recognizing and managing</u> |
| 206 | | <u>adverse events after placement.</u> |
| 207 | IV.A.1.b).(3).(c) | <u>using diagnostic and/or imaging studies relevant to the</u> |
| 208 | | <u>care of the patient, to include urinalysis.</u> |
| 209 | | |
| 210 | IV.A.1.c) | Medical Knowledge |
| 211 | | |
| 212 | IV.A.1.c).(1) | Fellows must demonstrate knowledge of established and |
| 213 | | evolving biomedical clinical, epidemiological, and social- |
| 214 | | behavioral sciences, as well as the application of this |
| 215 | | knowledge to patient care. Fellows must demonstrate |
| 216 | | knowledge of: |
| 217 | | |
| 218 | IV.A.1.c).(1).(a) | the scientific method of problem solving and |
| 219 | | evidence-based decision-making; |
| 220 | | |
| 221 | IV.A.1.c).(1).(b) | indications, contraindications, and techniques for, |
| 222 | | and limitations, complications, and interpretation of |
| 223 | | results of those diagnostic and therapeutic |
| 224 | | procedures integral to the discipline, including the |
| 225 | | appropriate indications for and use of screening |
| 226 | | tests and procedures; |
| 227 | IV.A.1.c).(1).(c) | clinical pharmacology, including drug metabolism, |
| 228 | | pharmacokinetics, and the effects of drugs on |
| 229 | | renal structure and function; |
| 230 | | |
| 231 | IV.A.1.c).(1).(d) | dialysis and extracorporeal therapy, including: |
| 232 | IV.A.1.c).(1).(d).(i) | artificial membranes used in hemodialysis and |
| 233 | | biocompatibility; |
| 234 | IV.A.1.c).(1).(d).(ii) | dialysis modes and their relation to |
| 235 | | metabolism; |
| 236 | | |
| 237 | IV.A.1.c).(1).(d).(iii) | dialysis water treatment, delivery systems, and |
| 238 | | reuse of artificial kidneys; |
| 239 | | |

| | | |
|-----|--------------------------|-----------------------------------------------------|
| 240 | IV.A.1.c).(1).(d).(iv) | kinetic principles of hemodialysis and |
| 241 | | peritoneal dialysis_ |
| 242 | IV.A.1.c).(1).(d).(v) | pharmacology of commonly used medications |
| 243 | | and their kinetic and dosage alteration with |
| 244 | | hemodialysis and peritoneal dialysis; |
| 245 | | |
| 246 | IV.A.1.c).(1).(d).(vi) | principles of dialysis access (acute and |
| 247 | | chronic vascular and peritoneal), to include |
| 248 | | indications, techniques, and complications;; |
| 249 | IV.A.1.c).(1).(d).(vii) | short- and long-term complications of each |
| 250 | | mode of dialysis and its management; and, |
| 251 | | |
| 252 | IV.A.1.c).(1).(d).(viii) | <u>technical and regulatory aspects of home and</u> |
| 253 | | <u>in-center dialysis;</u> |
| 254 | | |
| 255 | IV.A.1.c).(1).(d).(ix) | the indication for each mode of dialysis; |
| 256 | | |
| 257 | IV.A.1.c).(1).(d).(x) | urea kinetics and protein catabolic rate. |
| 258 | | |
| 259 | IV.A.1.c).(1).(e). | geriatric medicine, including: |
| 260 | | |
| 261 | IV.A.1.c).(1).(e).(i) | physiology and pathology of the aging |
| 262 | | kidney; and, |
| 263 | | |
| 264 | IV.A.1.c).(1).(e).(ii) | drug dosing and renal toxicity in elderly |
| 265 | | patients. |
| 266 | | |
| 267 | IV.A.1.c).(1).(f) | immunologic aspects of renal disease; |
| 268 | IV.A.1.c).(1).(g) | indications for and interpretations of radiologic |
| 269 | | tests of the kidney and urinary tract; |
| 270 | IV.A.1.c).(1).(h) | management of renal disorders in non-renal |
| 271 | | organ transplantation; |
| 272 | IV.A.1.c).(1).(i) | normal and abnormal blood pressure regulation; |
| 273 | IV.A.1.c).(1).(j) | normal and disordered fluid, electrolyte, and acid- |
| 274 | | base metabolism; |
| 275 | | |
| 276 | IV.A.1.c).(1).(k) | normal mineral metabolism and its alteration in |
| 277 | | renal diseases, metabolic bone disease, and |
| 278 | | nephrolithiasis; |
| 279 | | |
| 280 | IV.A.1.c).(1).(l) | nutritional aspects of renal disorders; |
| 281 | | |
| 282 | IV.A.1.c).(1).(m) | pathogenesis, natural history, and management of |
| 283 | | congenital and acquired diseases of the kidney and |
| 284 | | urinary tract, and renal diseases associated with |
| 285 | | systemic disorders; |

| | | |
|-----|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 286 | IV.A.1.c).(1).(n) | principles and practice of hemodialysis and peritoneal dialysis; |
| 287 | | |
| 288 | IV.A.1.c).(1).(o) | psychosocial and ethical issues of dialysis; |
| 289 | IV.A.1.c).(1).(p) | renal anatomy, physiology, and pathology; |
| 290 | | |
| 291 | IV.A.1.c).(1).(q) | renal transplantation, including: |
| 292 | IV.A.1.c).(1).(q).(i) | biology of transplantation rejection; |
| 293 | IV.A.1.c).(1).(q).(ii) | indications and contraindications for renal transplantation; |
| 294 | | |
| 295 | IV.A.1.c).(1).(q).(iii) | principles of transplant recipient evaluation and selection; |
| 296 | | |
| 297 | | |
| 298 | IV.A.1.c).(1).(q).(iv) | principles of evaluation of transplant donors, both living and cadaveric, to include histocompatibility testing; |
| 299 | | |
| 300 | | |
| 301 | | |
| 302 | IV.A.1.c).(1).(q).(v) | principles of organ harvesting, preservation, and sharing; |
| 303 | | |
| 304 | | |
| 305 | IV.A.1.c).(1).(q).(vi) | psychosocial aspects of organ donation and transplantation; and, |
| 306 | | |
| 307 | | |
| 308 | IV.A.1.c).(1).(q).(vii) | pathogenesis and management of acute renal allograft dysfunction. |
| 309 | | |
| 310 | | |
| 311 | IV.A.1.c).(1).(r) | technology of hemodialysis and peritoneal dialysis. |
| 312 | | |
| 313 | <u>IV.A.c).(2).</u> | <u>Fellows must demonstrate sufficient knowledge specific to the subspecialty of renal medicine (nephrology), including application of technology appropriate for the clinical context, to include evolving technologies.</u> |
| 314 | | |
| 315 | | |
| 316 | | |
| 317 | | |
| 318 | IV.A.1.d) | Practice-Based Learning and Improvement |
| 319 | | |
| 320 | IV.A.1.d).(1) | Fellows must demonstrate the ability to investigate and evaluate their care of patients, to appraise and assimilate scientific evidence, and to continuously improve patient care based on constant self-evaluation and lifelong learning. |
| 321 | | |
| 322 | | |
| 323 | | |
| 324 | | |
| 325 | | |
| 326 | IV.A.1.e) | Interpersonal and Communication Skills |
| 327 | IV.A.1.e).(1) | Fellows must demonstrate interpersonal and communication skills that result in the effective exchange of information and collaboration with patients, patients' families, and health professionals. |
| 328 | | |
| 329 | | |
| 330 | | |
| 331 | | |

332 IV.A.1.f) Systems-Based Practice
333
334 IV.A.1.f).(1) Fellows must demonstrate an awareness of and
335 responsiveness to the larger context and system of health
336 care, including the social determinates of health, as well as
337 the ability to call effectively on other resources in the
338 system to produce optimal care.
339

340 **IV.B. Regularly Scheduled Educational Activities**

341 IV.B.1. The educational program must include didactic instruction based on the
342 core knowledge content in renal medicine (nephrology).

343 IV.B.1.a) Fellows must have a sufficient number of didactic sessions to
344 ensure fellow-fellow and fellow-and-faculty member interaction.

345 IV.B.2. The program must ensure that fellows have an opportunity to review all
346 knowledge content from conferences that they could not attend.
347

348 IV.B.3. Fellows must have formal instruction in indications for and interpretation of
349 reports related to:

350
351 IV.B.3.a) balloon angioplasty of vascular access and other procedures
352 utilized in the maintenance of chronic vascular access patency;
353

354 IV.B.3.b) management of peritoneal catheters;
355

356 IV.B.3.c) radiology of vascular access;
357

358 IV.B.3.d) renal imaging; and,
359

360 IV.B.3.e) therapeutic plasmapheresis.

361 IV.B.4. Fellows must receive instruction in practice management relevant to renal
362 medicine (nephrology).
363

364 **IV.C. Clinical Experiences**

365 IV.C.1. Assignment of rotations must be structured to minimize the frequency of
366 rotational transitions, and rotations must be of sufficient length to provide a
367 quality educational experience, defined by continuity of patient care, ongoing
368 supervision, longitudinal relationships with faculty members, and meaningful
369 assessment and feedback.

370 IV.C.2. Rotations must be structured to allow fellows to function as a part of an
371 effective interprofessional team that works together toward the shared goals
372 of patient safety and quality improvement.

373 IV.C.3. Rotations must be structured to minimize conflicting inpatient and outpatient
374 responsibilities.
375

376 IV.C.4. At least 12 months of education must be devoted to clinical experience.
377

| | | |
|-----|---------------|------------------------------------------------------------------------|
| 378 | IV.C.4.a) | This must include at least four months of supervised involvement in |
| 379 | | dialysis therapy, including <u>both hemodialysis and peritoneal</u> |
| 380 | | <u>dialysis, to include:</u> |
| 381 | | |
| 382 | IV.C.4.a).(1) | assessment of hemodialysis and peritoneal dialysis |
| 383 | | efficiency; |
| 384 | | |
| 385 | IV.C.4.a).(2) | the complications of hemodialysis and peritoneal dialysis; |
| 386 | | |
| 387 | IV.C.4.a).(3) | determining special nutritional requirements of patients |
| 388 | | undergoing hemodialysis and peritoneal dialysis; |
| 389 | | |
| 390 | IV.C.4.a).(4) | end-of-life care and pain management for patients |
| 391 | | undergoing chronic hemodialysis and peritoneal dialysis; |
| 392 | | |
| 393 | IV.C.4.a).(5) | evaluation of end-stage renal disease patients for |
| 394 | | peritoneal dialysis and hemodialysis, and their instruction |
| 395 | | regarding these treatment options; |
| 396 | IV.C.4.a).(1) | <u>assessment of efficiency of peritoneal dialysis, home</u> |
| 397 | | <u>dialysis, and hemodialysis;</u> |
| 398 | | |
| 399 | IV.C.4.a).(2) | <u>determining special nutritional requirements of patients</u> |
| 400 | | <u>undergoing peritoneal dialysis, home hemodialysis, and</u> |
| 401 | | <u>hemodialysis::</u> |
| 402 | | |
| 403 | IV.C.4.a).(3) | <u>education and evaluation of pre-dialysis chronic kidney</u> |
| 404 | | <u>disease patients and dialysis patients regarding</u> |
| 405 | | <u>management of Stage 5 chronic kidney disease, including</u> |
| 406 | | <u>transplant, home dialysis modalities, in-center</u> |
| 407 | | <u>hemodialysis, and supportive care;</u> |
| 408 | | |
| 409 | IV.C.4.a).(4) | <u>end-of-life care and pain management for patients</u> |
| 410 | | <u>undergoing chronic peritoneal dialysis, home hemodialysis,</u> |
| 411 | | <u>and hemodialysis;the complications of peritoneal dialysis,</u> |
| 412 | | <u>home hemodialysis, and hemodialysis;</u> |
| 413 | | |
| 414 | IV.C.4.a).(5) | <u>evaluation and management of medical complications in</u> |
| 415 | | <u>patients during and between hemodialysis and peritoneal</u> |
| 416 | | <u>dialyses;</u> |
| 417 | | |
| 418 | IV.C.4.a).(6) | <u>evaluation and selection of patients for acute hemodialysis</u> |
| 419 | | <u>or continuous renal replacement therapies;</u> |
| 420 | | |
| 421 | IV.C.4.a).(7) | <u>examination of dialysis access for hemodialysis and</u> |
| 422 | | <u>peritoneal dialysis.</u> |
| 423 | IV.C.4.a).(8) | <u>longitudinal care of patients treated with home dialysis and</u> |
| 424 | | <u>in-center hemodialysis</u> |
| 425 | | |
| 426 | IV.C.4.a).(9) | <u>long-term follow-up of patients undergoing chronic</u> |
| 427 | | <u>hemodialysis, home dialysis, and peritoneal dialysis, and</u> |
| 428 | | <u>management of symptoms of ESRD;</u> |
| 429 | | |

| | | |
|-----|-----------------------|---------------------------------------------------------------------------------|
| 430 | IV.C.4.a).(10) | modification of drug dosage during hemodialysis and |
| 431 | | peritoneal dialysis; <u>and,</u> |
| 432 | <u>IV.C.4.a).(11)</u> | writing a hemodialysis, <u>home dialysis,</u> and peritoneal |
| 433 | | dialysis prescription and how to assess dialysis |
| 434 | | adequacy. |
| 435 | | |
| 436 | IV.C.5.a) | Fellows must have at least two months of clinical experience on an |
| 437 | | active renal transplant service, including supervised involvement in |
| 438 | | pre- and post-transplant care, including: |
| 439 | | |
| 440 | IV.C.5.a).(1) | clinical and laboratory diagnosis of all forms of rejection; |
| 441 | | |
| 442 | IV.C.5.a).(2) | evaluation and selection of transplant candidates; |
| 443 | | |
| 444 | IV.C.5.a).(3) | immediate post-operative management of transplant |
| 445 | | recipients, to include administration of |
| 446 | | immunosuppressants to a minimum of 10 new renal |
| 447 | | transplant recipients; |
| 448 | | |
| 449 | IV.C.5.a).(4) | management <u>ing</u> patients in the ambulatory setting for |
| 450 | | at least three months of at least 20 patients per fellow; |
| 451 | | |
| 452 | IV.C.5.a).(5) | medical management of rejection, to include use of |
| 453 | | immunosuppressive drugs and other agents; |
| 454 | | |
| 455 | IV.C.5.a).(6) | pre-operative evaluation and preparation of transplant |
| 456 | | recipients and donors; |
| 457 | | |
| 458 | IV.C.5.a).(7) | psychosocial and ethical issues of renal transplantation; |
| 459 | | and, |
| 460 | | |
| 461 | IV.C.5.a).(8) | recognition and medical management of the surgical and |
| 462 | | non-surgical complications of transplantations. |
| 463 | | |
| 464 | IV.C.5.b) | Each fellow must see at least 10 new renal transplant patients |
| 465 | | during the fellowship. |
| 466 | | |
| 467 | IV.C.5.b) | Fellows' clinical experience must include management of patients |
| 468 | | with renal disorders in the intensive care unit setting. |
| 469 | IV.C.5.c) | Fellows must have experience in the role of a renal medicine |
| 470 | | (nephrology) consultant in both the inpatient and outpatient |
| 471 | | settings. |
| 472 | IV.C.5.c) | <u>Fellows must have formal instruction regarding indications for</u> |
| 473 | | <u>and interpretation of the results of:</u> |
| 474 | | |
| 475 | <u>IV.C.5.c).(1)</u> | <u>balloon angioplasty of vascular access and other</u> |
| 476 | | <u>procedures utilized in the maintenance of chronic vascular</u> |
| 477 | | <u>access patency;</u> |
| 478 | | |
| 479 | <u>IV.C.5.c).(2)</u> | <u>management of peritoneal catheters;</u> |

| | | |
|-----|--------------------------|----------------------------------------------------------------------------------------|
| 480 | | |
| 481 | <u>IV.C.5.c).(3)</u> | <u>radiology of vascular access;</u> |
| 482 | | |
| 483 | <u>IV.C.5.c).(4)</u> | <u>renal imaging; and,</u> |
| 484 | | |
| 485 | <u>IV.C.5.c).(5)</u> | <u>therapeutic plasmapheresis.</u> |
| 486 | IV.C.6. | <u>The program must provide educational experiences in team-based care</u> |
| 487 | | <u>that allow fellows to interact with and learn from other health care</u> |
| 488 | | <u>professionals.</u> |
| 489 | IV.C.7. | <u>The educational program must provide fellows with elective experiences to</u> |
| 490 | | <u>allow them to participate in opportunities relevant to their future practice or</u> |
| 491 | | <u>to further skill/competence development.</u> |
| 492 | IV.C.7.a) | <u>When requested, additional training and experiences should be</u> |
| 493 | | <u>made available for fellows to achieve competence in the</u> |
| 494 | | <u>performance of:</u> |
| 495 | <u>IV.C.7.a).(1)</u> | <u>native or kidney biopsy; and,</u> |
| 496 | <u>IV.C.7.a).(2)</u> | <u>placement of temporary dialysis access.</u> |
| 497 | | |
| 498 | | |
| 499 | IV.C.8. | Fellows must participate in training using simulation. |
| 500 | | |
| 501 | IV.C.9. | Fellows should have a structured continuity ambulatory clinic experience |
| 502 | | <u>for the duration of the program</u> that exposes them to the breadth and depth |
| 503 | | of renal medicine (nephrology). |
| 504 | IV.C.9.e) | This should include an appropriate distribution of patients of each |
| 505 | | gender and a diversity of ages. |
| 506 | | |
| 507 | IV.C.9.a) | This experience should average one half-day each week |
| 508 | | throughout the education program. |
| 509 | | |
| 510 | IV.C.8.b) | Each fellow should, on average, be responsible for four to eight |
| 511 | | patients during each half-day session. |
| 512 | | |
| 513 | IV.C.8.b).(1) | Each fellow should, on average, be responsible for no more |
| 514 | | than eight to 12 patients during each half-day ambulatory |
| 515 | | session. |
| 516 | | |
| 517 | IV.C.9.b) | The continuing patient care experience should not be interrupted |
| 518 | | by more than one month, excluding a fellow's vacation. |
| 519 | | |
| 520 | IV.D. | Scholarly Activity |
| 521 | IV.D.1. | Fellows' Scholarly Activity |
| 522 | IV.D.1.a) | <u>While in the program, each fellow must complete at least one of the</u> |
| 523 | | <u>following scholarly activities: participation in grand rounds; poster</u> |
| 524 | | <u>presentations; workshops; quality improvement presentations;</u> |
| 525 | | <u>podium presentations; grant leadership; non-peer-reviewed</u> |

526 print/electronic resources, articles or publications; book chapters;
527 textbooks; webinars; service on professional committees; or service
528 as a journal reviewer, journal editorial board member, or editor.

529 IV.D.2. Faculty Scholarly Activity

530 See International Foundational Requirements, Section IV.D.2.

531
532 **V. Evaluation**

533
534 See International Foundational Requirements, Section V.

535
536 **VI. The Learning and Working Environment**

537
538 **VI.A. Principles**

539
540 See International Foundational Requirements, Section VI.A.

541
542 **VI.B. Patient Safety**

543
544 See International Foundational Requirements, Section VI.B.

545
546 **VI.C. Quality Improvement**

547
548 See International Foundational Requirements, Section VI.C.

549
550 **VI.D. Supervision and Accountability**

551 VI.D.1. Direct supervision of procedures performed by each fellow must occur
552 until competence has been acquired and documented by the program
553 director.

554
555 **VI.E. Professionalism**

556
557 See International Foundational Requirements, Section VI.E.

558
559 **VI.F. Well-Being**

560
561 See International Foundational Requirements, Section VI.F.

562
563 **VI.G. Fatigue**

564
565 See International Foundational Requirements, Section VI.G.

566
567 **VI.H. Transitions of Care**

568
569 See International Foundational Requirements, Section VI.H.

570
571 **VI.I. Clinical Experience and Education**

572
573 See International Foundational Requirements, Section VI.I.

574
575 **VI.J. On-Call Activities**

576
577

See International Foundational Requirements, Section VI.J.